PODIUM - Q&A Sessions

• PODIUM with Dr. Denis Lacombe (No. 12, July 2010)

• PODIUM - Non-adherence: a new epidemic? - with Dr. Ann Partridge  (No. 12, August 2010)

• PODIUM - EORTC: Fit for the Future - with Professor Jean-Yves Blay (No. 9, June 2010)

• PODIUM -Halting metastasis: a new possibility in the clinic - with Dr Patricia Steeg (No. 8, April 2010)

• PODIUM - An insight into the changing features of drug approvals - with Prof. Hubert Leufkens (No. 6, April 2010)

• PODIUM - A window of opportunity in drug development - with Prof. Lilian Siu (No. 5, March 2010)

• PODIUM - Encouraging partnership across the income divide - with Dr Ian Magrath  (No. 4, March 2010)

• PODIUM - Taking the long term view - with Professor Andrew Lister (No. 3, February 2010)

• PODIUM - ‘The tide is turning’ in the breast screening debate - with Hazel Thornton (No.2 January 2010)

• PODIUM - Creating a healing environment - with Professor Christoffer Johansen (No. 1, January 2010)

• PODIUM - HPV testing ‘needed now’ - with  Professor Jack Cuzick (No. 18, December 2009)

• PODIUM - ‘We need a major shift in research priorities’ -  with Professor Richard Sullivan (No. 17, December 2009)

• PODIUM - New strings to ECCO’s bow – with Professor Michael Baumann  (No. 16, November 2009)
• PODIUM - Relapsed ovarian cancer: no rush to start treatment – with Professor Gordon Rustin (No. 14, September 2009)
• PODIUM - Eurocancercoms  - with Professor Gordon McVie (No. 12, July 2009)
• PODIUM - The problem with chemoprevention – with Professor John Potter  (No. 12, July 2009)
• PODIUM - The State of Denmark - with Dr. Hans Storm (No. 10, July 2009)
• PODIUM - MINDACT:Complex trials ‘are feasible’ -  with Dr. Fatima Cardoso (No. 9, June 2009)
• PODIUM - What Darwin can tell us about cancer – with Professor Richard Sullivan (No. 8, May 2009)
• PODIUM - Introducing EJC’S new translational editor!  – with Professor Christof von Kalle No. 7, May 2009)
• PODIUM - The need for a new framework in drug development – with Professor Sir James Black (No. 5, Mar. 2009)
• PODIUM - Metastasis suppression: the way ahead – with Dr Patricia Steeg (No. 4, Mar. 2009)
• PODIUM - Survival gap narrows in Europe - with Dr Riccardo Capocaccia (No. 3, Jan. 2009)
• PODIUM - The Stockholm Declaration – with Professor Ulrik Ringborg (No. 1, Jan. 2009)
• PODIUM - NOCI set to launch first major trial–  with Professor Martine Piccart-Gebhart (No. 17, Nov. 2008)
• PODIUM - Cancer research in Europe: What next?– with Professor Richard Sullivan (No. 15, Oct. 2008)
• PODIUM - Social inequalities and cancer - with Dr Susanne Oksbjerg Dalton (No. 13, Sept. 2008)
• PODIUM - Oestrogen: An overlooked chemopreventive agent for prostate cancer?- with Professor Emeritus Louis Denis (No. 12,  Aug. 2008)
• PODIUM - Learning to communicate with dying patients – with Dr. Jane Turner  (No. 11, Jul. 2008)
• PODIUM - Cross-over trials ‘dilute the data base’ – with Prof. Jonas Bergh (No. 9, Jun. 2008
• PODIUM - Palliative care at a crossroads - with Prof. Marie Fallon (No. 7, May 2008)
• PODIUM - Cancer Control in Europe - with Prof. Jan Willem Coebergh (No. 6, Apr. 2008)
• PODIUM - Cancer trends in Europe – with Henrike Karim-Kos (No. 5,  Mar. 2008)
• PODIUM - Keep taking the tablets! – with Dr. Ron Mathijssen (No. 4, Mar. 2008)
• PODIUM - Introducing radiotherapy to Oman - with Dr. B. K. Mohanti (No. 3, Feb. 2008)
• PODIUM - Novel trial designs for novel agents - with Dr. Richard Simon (No. 2, Jan. 2008)
• PODIUM - Relief as BRCA1 patent remains curtailed - with Prof. Gert Matthijs (No. 1, Jan. 2008)
• PODIUM - Elderly patients: the forgotten majority - with Dr. Riccardo Audisio (No. 16, Nov. 2007)
• PODIUM - with Professor V Craig Jordan (No. 9, Jun. 2007)

EUROFILE

• EUROFILE - An overhaul of the Clinical Trials Directive (No. 9, June 2010)
• EUROFILE - Pharmacovigilance changes: For better or worse? (No. 8, May 2010)
• EUROFILE - A snapshot of cancer in Europe (No. 6, April 2010)
• EUROFILE - Towards European consensus on rare diseases (No. 5, March 2010)
• EUROFILE - EU seeks research harmony through Joint Programming (No. 2, January 2010)
• EUROFILE - The Working Time Directive goes live  (No. 16, November 2009)
• EUROFILE - Putting the EU plan into action  (No. 14, September 2009)
• EUROFILE – Cancer a priority in IMI’s second round (No. 12, July 2009)
• EUROFILE – What the elections mean for cancer (No. 10, July 2009)
• EUROFILE - Partnership aims to turn cancer plans into reality (No. 8, May 2009)
• EUROFILE: The impact of the economic recession (No. 5, Mar. 2009)
• EUROFILE: Proposed new law on animal experimentation (No. 3, Jan. 2009)
• EUROFILE: Research councils tackle clinical trials directive (No. 1, Jan. 2009)
• EUROFILE - Progress in cancer screening? (No. 15, Oct. 2008)
• EUROFILE - A Cancer Action Plan for Europe (No. 13, Sept. 2008)
• EUROFILE- Towards a more effective EU legal framework - with Dr Colette Lukan (No. 12, Aug. 2008)
• EUROFILE - Finding platform for translational cancer research
(No. 11, Jul. 2008)
• EUROFILE - Spain shines in European frontier research scheme (No. 9, Jun. 2008)
• EUROFILE - Speaking up for medical research (No. 6, Apr. 2008)
• EUROFILE - Research networks look for longer life (No. 4, Mar. 2008)
• EUROFILE - Private-public drive to cut delays in drug development (No. 2, Jan. 2008)
• EUROFILE - Slovenian Presidency makes cancer a priority (No. 1, Jan. 2008) 
• EUROFILE - EC Directive - use of MRI (No. 12, Aug. 2007)
• EUROFILE - Deadline approaches for animal experimentation directive (No. 16, Nov.  2007) 

News

• The last hurdle for erlotinib (No. 10, July 2010)

• Immunotherapy approved for prostate cancer (No. 10, July 2010)

• European paediatric research network is set to go (No. 10, July 2010)

• Palliative care for children (No. 10, July 2010)

• Misconceptions about end-of-life drugs (No. 10, July 2010)

• Over-diagnosis in thyroid cancer? (No. 10, July 2010)

• European workshop on stem-cell research (No. 10, July 2010)

• Stereotactic radiotherapy in brain cancer (No. 10, July 2010)

• Once-only colorectal test is ‘safe and practical’ (No. 9, June 2010)

• ‘Substantial differences’ in lung cancer survival (No. 9, June 2010)

• No-go for azacitidine in UK (No. 8, May 2010)

• New CONSORT statement released (No. 8, May 2010)

• Survival benefit after contralateral mastectomy (No. 6, April 2010)

• Split course radiotherapy in NSCLC (No. 6, April 2010)

• Six-point plan for safer radiotherapy (No. 6, April 2010)

• Shorter radiotherapy schedule in breast cancer  (No. 6, April 2010)

• Pain relief ‘is a human rights issue  (No. 6, April 2010)

• Clinical Trials Directive to be amended? (No. 5, March 2010)

• Ofatumumab in CLL (No. 5, March 2010)

• World Cancer Day focuses on infections  (No. 5, March 2010)

• Tobacco control: challenges for the 21^st century  (No. 5, March 2010)

• Vitamin D levels linked to risk of colon cancer  (No. 5, March 2010)
• … but clinical trial on RNAi is allowed  (No. 4, March 2010)
• FDA’s deliberations on erlotinib continue…  (No. 4, March 2010)
• Stem cells ‘also suppress immune response’ (No. 4, March 2010)
• Contaminated cell lines found in oesophageal cancer (No. 4, March 2010)
• HPV testing ‘prevents more cervical cancers than cytology’ (No. 4, March 2010)
• The need for cardio-oncology (No. 3, February 2010)
• Cardiac outcomes in survivors of childhood cancers (No. 3, February 2010)
• Late diagnosis in England (No. 3, February 2010)
• Obesity ‘could wipe out benefits of smoking cessation’ (No. 3, February 2010)
• Androgen deprivation therapy linked to heart disease (No. 3, February 2010)
• EAU and Europa Uomo join hands (No. 3, February 2010)
• Time to raise the bar for cancer drug approval? (No. 3, February 2010)
• Cancer mortality: favourable trends continue (No. 2, January 2010)
• New lung cancer staging classification discussed (No. 2, January 2010)
• NICE says no to bevacizumab… (No. 2, January 2010)
• … yes to oral topotecan (No. 2, January 2010)
• Accelerated approval for ofatumumab
• ‘Thromboembolism risk’ with erythropoiesis agents (No. 2, January 2010)
• Ambulight receives CE Mark (No. 2, January 2010)
• Call for ‘two way’ translational research (No. 2, January 2010)
• Nobel Prize for telomere and telomerase research (No. 2, January 2010)
• Campaign to safeguard the future of MRI (No. 1, January 2010)

• The need for a new strategy on clinical trials (No. 16, November 2009)

• Zalutumumab: partial hold lifted (No. 14, September 2009)

• No-go for cetuximab in NSCLC (No. 14, September 2009)

• Thalidomide ‘does not improve survival’ in SCLC (No. 14, September 2009)

• New genetic link to ovarian cancer (No. 14, September 2009)

• Euthanasia and palliative care ‘can co-exist’ (No. 14, September 2009)

• Sunbeds reclassified as Group 1 carcinogen (No. 14, September 2009)

• ‘Serious concerns’ about health evaluation methods (No. 14, September 2009)

• Cervical screening for under 25s ‘has little impact’ (No. 14, September 2009)

• Pezcoller Award for Scientific Leadership  (No. 13, August 2009)
• Is paperwork suffocating British clinical research? (No. 13, August 2009)
• Cross-protection from HPV vaccine (No. 13, August 2009)
• Racial disparities in survival (No. 13, August 2009)
• Mammography: ‘a close call’ (No. 13, August 2009)
• Cancer, the environment, and a (critical) friend remembered (No. 13, August 2009)
• A boost to communications in Europe (No. 13, August 2009)
• Partial hold on zalutumumab studies (No. 12, July 2009)
• Ofatumumab in CLL (No. 12, July 2009)
• NICE approval of cetuximab (No. 12, July 2009)
• Positive opinion for pemetrexed (No. 12, July 2009)
• Statistician recognised at St Gallen (No. 12, July 2009)
• Chemotherapy planning tool revised (No. 12, July 2009)
• UK moves to increase data sharing (No. 12, July 2009)
• European Action Against Rare Cancers (No. 12, July 2009)
• Sound waves treat prostate cancer (No. 12, July 2009)
• Cancer and Schizophrenia (No. 12, July 2009)
• The dangers of green tea (No. 12, July 2009)
• Unexpected dietary links with cancer (No. 12, July 2009)
• Call for international action on non-communicable diseases (No. 10, July 2009)
• Population screening for prostate cancer? Not recommended (No. 10, July 2009)
• UK consensus on renal cancer (No. 10, July 2009)
• Cord blood transplants ‘on the increase’  (No. 9, June 2009)
• Acrylamide ‘not linked’ to lung cancer risk (No. 9, June 2009)
• Anti-tobacco campaigner wins lifetime award (No. 9, June 2009)
• Future of cancer care – further financial headaches? (No. 8, May 2009)
• Rigorous approach needed’ to find preventive agents (No. 8, May 2009)
• Cancer vaccines: breakthrough imminent? (No. 8, May 2009)
• Paradox of anti-angiogenic drugs (No. 8, May 2009)
• HIV therapy: a revolutionary new direction? (No. 8, May 2009)
• Chemoprevention in prostate cancer (No. 8, May 2009)
• First reading of EU’s animal research report  (No. 8, May 2009)
• Eurocourse: a welcome boost for cancer registries (No. 7, May 2009)
• Ovarian screening ‘is feasible’ (No. 7, May 2009)
• Fertility drugs ‘do not increase risk of ovarian cancer’ (No. 7, May 2009)
• Recognition for research in public health (No. 7, May 2009)
• Aspirin ‘cuts gastric cancer risk’ (No. 5, Mar. 2009)
• World Cancer Day: Focus on excess body weight (No. 5, Mar. 2009)
• Cetuximab ‘lowers survival and quality of life’ (No. 5, Mar. 2009)
• NICE reversal on myeloma and kidney cancer drugs (No. 5, Mar, 2009)
• EMEA consults on orphan drugs .. (No. 5, Mar. 2009)
• … and establishes a new committee (No. 5, Mar. 2009)
• Lingering objections to EC’s pharmaceutical vision (No. 5, Mar. 2009)
• Feasibility of screening (No. 4, Mar. 2009)
• The need for better policies on indoor radon (No. 4, Mar. 2009)
• Marker for lung cancer treatment (No. 4, Mar. 2009)
• HPV in lung cancer (No. 4, Mar. 2009)
• Hormones and cancer (No. 4, Mar, 2009)
• MBT ‘may be a human carcinogen’ (No. 4, Mar. 2009)
• Positive opinion for degarelix (No. 4, Mar. 2009)
• Adjuvant chemotherapy in pancreatic cancer (No. 4, Mar. 2009)
• NICE: New criteria for end-of-life medicines (No. 4, Mar. 2009)  
• Extended indication for cetuximab (No. 3, Jan. 2009)
• New publisher for EJC (No. 3, Jan. 2009)
• Mandate for change in lung cancer (No. 3, Jan. 2009)
• Standardisation of CML treatment (No. 1, Jan. 2009)
• Genetic susceptibility to lung cancer (No. 1, Jan. 2009)
• Molecular basis for tamoxifen resistance (No. 1, Jan. 2009)
• BRAF mutations ‘cause resistance to therapy’ (No. 1, Jan. 2009)
• Workload reduced by updated RECIST (No. 1, Jan. 2009)
• RCTs ‘on an undeserved pedestal’ ‘Judgement needed’ in analysis of evidence (No. 1, Jan. 2009)

• Drug development: No risk, no fun (No. 17, Nov. 2008)

• Vitamin C ‘may antagonise cancer therapy’ (No. 17, Nov. 2008)
• Quality of surgery in colon cancer (No. 17, Nov. 2008)
• Computer-aided detection of breast cancer (No. 17, Nov. 2008)
• Single jab for testicular cancer (No. 17, Nov. 2008)
• Nobel Prize for the discovery of HPV (No. 17, Nov. 2008)
• End of the road for yet another melanoma vaccine - Time to pause and rethink (No. 16, Oct. 2008)
• WHO tackles behaviour change (No. 16, Oct. 2008)
• Bortezomib in multiple myeloma (No. 16, Oct. 2008)
• Scottish turnaround on pemetrexed (No. 16, Oct. 2008
• Licence update for cetuximab (No. 15, Oct. 2008)
• Disappointment over NICE’s ruling on kidney drugs (No. 15, Oct. 2008)
• Giving bad news (No. 15, Oct. 2008)
• Obesity and pancreatic cancer risk in women (No. 13, Sept. 2008)
• What colour is my cancer? (No. 13, Sept. 2008)
• New drug in palliative care (No. 13, Sept. 2008)
• Urgent need for action’ on colorectal cancer (No. 12, Aug. 2008)
• Screening compliance and risk of cervical cancer (No. 12, Aug. 2008)
• ‘Sad irony’ of modern radiotherapy (No. 11, Jul. 2008)
• New Director at IARC (No. 11, Jul. 2008)
• Risk of second cancer after non-Hodgkin’s lymphoma (No. 9, Jun. 2008)
• Processed food and breast cancer risk (No. 9, Jun. 2008)
• New guidelines on extravasation management (No. 9, Jun. 2008)
• ECCO and ESMO reach compromise (No. 9, Jun. 2008)
• New initiatives from ECCO (No. 7, May 2008)
• Launch of European CRC awareness month (No. 7, May 2008)
• Infused 5FU ‘better than bolus’ (No. 7, May 2008)
• Education and cancer mortality (No. 7, May 2008)
• More intense chemotherapy in neuroblastoma (No. 7, May 2008)
• MRI Directive postponed (No. 7, May 2008)
• Accelerated approval of bevacizumab (No. 7, May 2008)
• Stop cervical cancer! (No. 6, Apr. 2008)
• ‘Catastrophic smoking epidemic’ in India (No. 6, Apr. 2008)
• Language mapping in glioma surgery (No. 5, Mar. 2008)
• Drugs approvals in metastatic colorectal cancer (No. 5, Mar. 2008)
• ‘Increased public support’ for use of human tissue in research (No. 5, Mar. 2008)
• The Pill ‘halves the risk of ovarian cancer’ (No. 5, Mar. 2008)
• An ‘explosion’ of cancer expected by 2030 (No. 5, Mar. 2008)
• New indication for bevacizumab (No. 4, Mar. 2008)
• ‘Small benefit’ from chemotherapy in colorectal cancer (No. 4, Mar. 2008)
• Radiotherapy ‘as good as surgery’ for bladder cancer (No. 4, Mar. 2008)
• Positive news in colorectal cancer… (No. 3, Feb. 2008)
• …. And in advanced breast cancer (No. 3, Feb. 2008)
• Missing protein ‘could improve selection for paclitaxel’ (No. 3, Feb. 2008)
• Young scientists investigate pain (No. 3, Feb. 2008)
• A new chapter begins for EORTC (No. 3, Feb. 2008)
• Thalidomide in myeloma (No. 2, Jan. 2008)
• Chemotherapy for Hodgkin’s lymphoma No. 2, Jan. 2008)
• New Communications Manager at ECCO (No. 2, Jan. 2008)
• EU Directive postponed to protect MRI (No. 2, Jan. 2008)
• Need for a paradigm shift in clinical trial design (No. 2, Jan. 2008)
• Stem cell researchers ‘face prosecution’ (No. 16, Nov. 2007)
• Bevacizumab in lung cancer (No. 16, Nov. 2007)
• Nelarabine approved in Europe (No. 16, Nov. 2007)
• Eurocare-4 (No. 16, Nov. 2007)
• Early drug design: Task force reports (No. 16, Nov. 2007)
• Global framework required’ for research (No. 16, Nov. 2007)
• Link between low cholesterol levels and cancer (No. 14, Sep. 2007)
• First common bowel cancer gene found (No. 14, Sep. 2007)
• Group therapy ‘does not improve survival’ (No. 14, Sep. 2007)
• Positive opinion for trabectedin (No. 14, Sep. 2007)
• New indication for bevacizumab (No. 14, Sep. 2007)
• Delaying radiotherapy in children (No. 14, Sep. 2007)
• Quality of Life in Spain (No. 14, Sep. 2007)
• Stem cell researchers ‘face prosecution’ (No. 16, Nov. 2007)
• A lifetime in breast cancer research (No. 10, Jul. 2007)

Meeting Reports

• ASCO: 46th Annual Meeting (No. 12, July 2010)
• Clinical trials system in crisis
• PARP inhibition in ovarian cancer
• Bevacizumab ‘prolongs progression-free survival’
• Anew era in melanoma?
• End of the line for ganglioside vaccine
• ALK inhibitor shows ‘impressive activity’
• Axillary node dissection unnecessary?
• Selenium ‘doesn’t help’
• 2^nd European Lung Cancer Conference  (No. 10, July 2010)
• CXCR4 ‘may be a new target’
• Closer co-operation essential for personalised therapy
• Targeting anti-angiogenesis treatment
• Finding ‘cold spots’ may minimise side-effects
• AACR 101st Annual Meeting (No. 9, June 2010)
• BATTLE against lung cancer
• An early marker for breast cancer?
• Statins ‘do not protect against colorectal cancer’
• Risk assessment in prostate cancer

• 7th European Breast Cancer Conference  (No. 8, May 2010)

• Mastectomy versus breast conserving surgery

• PARP expression ‘in all subtypes’
• Specific lymph node radiotherapy
• New marker for anthracycline response
• Pregnant women ‘can receive chemotherapy’
• ‘Cooling off’ period before mastectomy
• The San Antonio Breast Cancer Symposium   (No. 4, March 2010)
• Notch inhibitors and breast cancer stem cells
• Anti-oestrogens ‘may protect against lung cancer’
• Dual HER2 therapy ‘may extend survival’
• Bisphosphonates ‘may reduce breast cancer’
• Antidepressants and tamoxifen
• 51^st Annual Meeting of American Society of Hematology (No. 3, February 2010)
• Nilotinib ‘more effective than imatinib’
• Omacetaxine ‘shows promise in T135I-mutated CML
• Rituximab ‘produces overall survival advantage’
• Bendamustine ‘superior to CHOP’ in follicular lymphoma
• 3rd Meeting report: Joint ECCO 15-34th ESMO Multidisciplinary Congress (No. 1, January 2010)
  • Young voices ‘are not being heard'
  • Imaging biomarkers and RECIST
• The 16th International Meeting, European Society of Gynaecological Oncology (ESGO)  (No. 1, January 2010)
  • Supplements ‘increase uterine cancer risk’
  • Cancer treatment during pregnancy ‘need not risk baby’s health
  • Ovarian cancer ‘should be treated by experts’
  • HPV vaccination for boys
• 2nd Meeting report: Joint ECCO 15-34th ESMO Multidisciplinary Congress (No. 18, December 2009)
  • Launch of European Academy of Cancer Sciences
  • Regional hyperthermia in soft-tissue sarcoma
  • Trastuzumab ‘provides survival benefit in gastric cancer’
  • Aspirin ‘cuts colorectal cancer risk’
  • Sorafenib ‘active in advanced breast cancer’
  • Divorce rate ‘not affected’ by childhood cancer
  • Sunitinib in pancreatic cancer…
  • ...and in GIST
• 1st Meeting report: Joint ECCO 15-34th ESMO Multidisciplinary Congress (No. 17, December 2009)
  • New drug shows promise for metastatic melanoma
  • PARP inhibitor ‘effective in metastatic breast cancer’
  • Trastuzumab ‘provides survival benefit in gastric cancer’
  • ECCO/EJC Young Investigators Award
  • The launch of the European Partnership
  • Prostate cancer hormone therapy ‘raises heart disease risk’ 
• The American Society of Clinical Oncology Annual Meeting (No. 11, July 2009)
  • PARP inhibitors ‘active’ in advanced breast cancer
  • ‘No benefit’ from CA125 testing for relapse
  • Cancer vaccines ‘show promise’
  • HRT link to lung cancer death
  • Trastuzumab improves survival in gastric cancer
  • New standard of care in neuroblastoma?
  • Maintenance pemetrexed extends survival in lung cancer
  • Bevacizumab ‘unsuccessful’ in colon cancer
• American Association for Cancer Research (AACR) 100^th Annual Meeting (No. 9, June 2009)
  • New hope in pancreatic cancer
  • Signs of CLL ‘years before diagnosis’
  • Urine test for lung cancer?
  • Designer T cells in prostate cancer
  • Molecular profiling in advanced cancer
  • Walnuts ‘may fight breast cancer’
  • Gene mutations impair response to therapies in mCRC
• European Association of Urology (EAU) Meeting (No. 8, May 2009)
  • Optimising outcomes in RCC
• 31^st Annual San Antonio Breast Cancer Symposium (No. 3, Jan. 2009)
  • Breast density ‘indicates tamoxifen efficacy’
  • Zoledronic acid ‘shrinks tumours’
  • BIG data on letrozole
  • Chromosome test for personalised treatment 
• 33^rd European Society for Medical Oncology Congress (No. 16, Oct. 2008)
  • Gefitinib in NSCLC
  • Trabectedin in ovarian cancer
  • Head and neck cancer
  • Intravenous iron
  • Cost analysis of kidney cancer drugs
• 13th European Hematology Association Meeting (No. 13, Sept. 2008)
  • Molecular testing in CML
• 44th American Society of Clinical Oncology (ASCO) Meeting (Full Text, No. 13, Sept. 2008)
  • Cetuximab in NSCLC: caution urged
  • Genetic signature ‘may predict aggressiveness’ of NSCLC
• 44th American Society of Clinical Oncology (ASCO) Meeting (Full Text,  No. 12, Aug. 2008)
  • Experimental agent ‘shows benefit’ in renal cell carcinoma
  • Vitamin D deficiency linked to breast cancer
  • Gemcitabine ‘doubles pancreatic cancer survival’
  • Narcolepsy drug ‘alleviates fatigue’
  • Vaginal brachytherapy: New treatment of choice for endometrial cancer?
  • Zoledronic acid ‘benefits women with early breast cancer’
• 44th American Society of Clinical Oncology (ASCO) Meeting (Full Text, No. 11, Jul. 2008)
  • KRAS status and targeted treatment
  • Survival extended in mRCC
• 6^th European Breast Cancer Conference (EBCC-6) (Full Text, No. 9, Jun. 2008)
  • Mammography to age 75
  • Specialist nurses ‘could save countries millions’
  • MRI before surgery ‘should become standard’
  • Pregnant patients ‘should receive standard treatment’
• 1st Asian Breast Cancer Conference (No. 7, May 2008)
  • Multiple targeted agents in advanced breast cancer
• ASCO GI Meeting (Full Text, No. 6, Apr. 2008)
  • Shall we agree to disagree?
• San Antonio Breast Cancer Symposium (Full Text, No. 5, Mar. 2008)
  • Tamoxifen: ‘10 years is better than 5’
  • ATAC: the first 100 months
  • Capecitabine plus trastuzumab ‘improves outcomes’
  • Mitch Dowsett wins William L McGuire Award
  • Trastuzumab after progression
• 49th Annual Meeting of American Society of Hematology Meeting Report (Full Text, No. 4, Mar. 2008)
  • Dasatinib after imatinib in CML
  • BEACOPP in Hodgkin’s lymphoma
  • ‘Less is more’ with dexamethasone
  • Consolidation in follicular lymphoma
• AACR-NCI-EORTC: Molecular Targets and Cancer Therapeutics Meeting Report (Full Text, No. 2, Jan. 2008)
  • Introduction
  • First in Class and Novel Agents
  • Anti-angiogenesis and Functional Imaging
  • Molecular Markers and Patient Selection
  • Rational Drug Combination
• 14th European Cancer Conference (ECCO) Meeting Report (Full Text, No. Nov., 2007)
  • Introducing ECCO
  • FECS/EJC Award
  • Protecting patients’ rights in Italy
  • ZD4054 ‘prolongs survival in prostate cancer’
  • Gemcitabine ‘delays progression of pancreatic cancer’
  • Endometrial cancer: Change in practice
  • Surgical outcomes under scrutiny
  • COX2 mutation linked to ovarian cancer
  • Blood test ‘may detect recurrence’
  • Nursing Awards
  • Axitinib ‘shows promise in kidney cancer’
  • New class of melanoma drug
  • ECCO: The Way Ahead